T-Cell Immunotherapy Market Research Report by Mechanism Of Action (Active Immunotherapy and Passive Immunotherapy), Product Class, Type of Therapy, Indication, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030- Product Image

Sale

T-Cell Immunotherapy Market Research Report by Mechanism Of Action (Active Immunotherapy and Passive Immunotherapy), Product Class, Type of Therapy, Indication, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

Report
245 Pages
July 2022
Region: Global
360iResearch™
ID: 4986070

UP TO €856EUR$895USD£752GBP OFF until Mar 31^st 2023

The Global T-Cell Immunotherapy Market size was estimated at USD 5,309.89 million in 2022, USD 5,984.33 million in 2023, and is projected to grow at a CAGR of 12.93% to reach USD 14,047.63 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global T-Cell Immunotherapy Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global T-Cell Immunotherapy Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global T-Cell Immunotherapy Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global T-Cell Immunotherapy Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global T-Cell Immunotherapy Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Mechanism Of Action, the market is studied across Active Immunotherapy and Passive Immunotherapy.
Based on Product Class, the market is studied across Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy.
Based on Type of Therapy, the market is studied across CAR-T, TCR, and TIL.
Based on Indication, the market is studied across B-cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global T-Cell Immunotherapy Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global T-Cell Immunotherapy Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global T-Cell Immunotherapy Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global T-Cell Immunotherapy Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global T-Cell Immunotherapy Market, including Adaptimmune Therapeutics PLC, Apac Biotech, Atara Biotherapeutics, Inc., Autolus Limited, bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics, Ltd, Cellectis SA, Chimera Bioengineering, Dendreon Pharmaceuticals LLC, Eureka Therapeutics, Inc., Gilead Sciences, Inc., Green Cross Corporation, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Inc., JW CreaGene Co., Ltd., LAVA Therapeutics BV, Lyell Immunopharma, Neogene Therapeutics, NeoTX Therapeutics, Novartis AG, Oxford Vacmedix, Poseida Therapeutics, TScan Therapeutics, Inc., Xenetic Biosciences, and ZIOPHARM Oncology.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global T-Cell Immunotherapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global T-Cell Immunotherapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global T-Cell Immunotherapy Market?
4. What is the competitive strategic window for opportunities in the Global T-Cell Immunotherapy Market?
5. What are the technology trends and regulatory frameworks in the Global T-Cell Immunotherapy Market?
6. What is the market share of the leading vendors in the Global T-Cell Immunotherapy Market?
7. What modes and strategic moves are considered suitable for entering the Global T-Cell Immunotherapy Market?

Frequently Asked Questions about the Global T-Cell Immunotherapy Market

What is the estimated value of the Global T-Cell Immunotherapy Market?

The Global T-Cell Immunotherapy Market was estimated to be valued at $5309.89 Million in 2022.

What is the growth rate of the Global T-Cell Immunotherapy Market?

The growth rate of the Global T-Cell Immunotherapy Market is 12.9%, with an estimated value of $14047.63 Million by 2030.

What is the forecasted size of the Global T-Cell Immunotherapy Market?

The Global T-Cell Immunotherapy Market is estimated to be worth $14047.63 Million by 2030.

Who are the key companies in the Global T-Cell Immunotherapy Market?

Key companies in the Global T-Cell Immunotherapy Market include Adaptimmune Therapeutics PLC, Apac Biotech, Atara Biotherapeutics, Inc., Autolus Limited, bluebird bio, Inc., Bristol, Myers Squibb Company, CARsgen Therapeutics, Ltd and Chimera Bioengineering.

Report Attribute	Details
No. of Pages	245
Published	July 2022
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 5309.89 Million
Forecasted Market Value ( USD ) by 2030	$ 14047.63 Million
Compound Annual Growth Rate	12.9%
Regions Covered	Global
No. of Companies Mentioned	26

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Cancer and Autoimmune Diseases
5.1.1.2. Use of Cell-Based Targeted Therapies
5.1.1.3. Increasing R&D Supporting T-cell Immunotherapy
5.1.2. Restraints
5.1.2.1. High Cost of Treatment
5.1.3. Opportunities
5.1.3.1. Commercialisation and Funding by Pharmaceutical Companies
5.1.3.2. Attractiveness of Off-the-Shelf Therapies
5.1.4. Challenges
5.1.4.1. Neurologic Toxicities and Cytokine Release Syndrome
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. T-Cell Immunotherapy Market, by Mechanism Of Action
6.1. Introduction
6.2. Active Immunotherapy
6.3. Passive Immunotherapy

7. T-Cell Immunotherapy Market, by Product Class
7.1. Introduction
7.2. Bispecific Antibodies
7.3. Cytokines
7.4. Monoclonal Antibodies
7.5. Oncolytic Virus Therapy

8. T-Cell Immunotherapy Market, by Type of Therapy
8.1. Introduction
8.2. CAR-T
8.3. TCR
8.4. TIL

9. T-Cell Immunotherapy Market, by Indication
9.1. Introduction
9.2. B-cell Malignancies
9.3. Liver Cancer
9.4. Prostate Cancer
9.5. Renal Cell Carcinoma

10. Americas T-Cell Immunotherapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific T-Cell Immunotherapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa T-Cell Immunotherapy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Product Portfolio Analysis, By Key Player
13.5. Competitive Scenario
13.5.1. Merger & Acquisition
13.5.2. Agreement, Collaboration, & Partnership
13.5.3. New Product Launch & Enhancement
13.5.4. Investment & Funding
13.5.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Adaptimmune Therapeutics PLC
14.2. Apac Biotech
14.3. Atara Biotherapeutics, Inc.
14.4. Autolus Limited
14.5. bluebird bio, Inc.
14.6. Bristol-Myers Squibb Company
14.7. CARsgen Therapeutics, Ltd
14.8. Cellectis SA
14.9. Chimera Bioengineering
14.10. Dendreon Pharmaceuticals LLC
14.11. Eureka Therapeutics, Inc.
14.12. Gilead Sciences, Inc.
14.13. Green Cross Corporation
14.14. Innovative Cellular Therapeutics
14.15. Iovance Biotherapeutics, Inc.
14.16. JW CreaGene Co., Ltd.
14.17. LAVA Therapeutics BV
14.18. Lyell Immunopharma
14.19. Neogene Therapeutics
14.20. NeoTX Therapeutics
14.21. Novartis AG
14.22. Oxford Vacmedix
14.23. Poseida Therapeutics
14.24. TScan Therapeutics, Inc.
14.25. Xenetic Biosciences
14.26. ZIOPHARM Oncology

15. Appendix
15.1. Discussion Guide
15.2. License & PricingList of Figures
FIGURE 1. GLOBAL T-CELL IMMUNOTHERAPY MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL T-CELL IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET DYNAMICS
FIGURE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2022 VS 2030 (%)
FIGURE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL T-CELL IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY MECHANISM OF ACTION, 2030
FIGURE 15. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2022 VS 2030 (%)
FIGURE 18. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT CLASS, 2030
FIGURE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
FIGURE 21. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
FIGURE 22. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
FIGURE 24. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2022 VS 2030 (%)
FIGURE 25. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 26. GLOBAL T-CELL IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE OF THERAPY, 2030
FIGURE 27. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, 2018-2030 (USD MILLION)
FIGURE 28. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, 2018-2030 (USD MILLION)
FIGURE 29. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, 2018-2030 (USD MILLION)
FIGURE 30. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 31. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 32. GLOBAL T-CELL IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
FIGURE 33. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, 2018-2030 (USD MILLION)
FIGURE 34. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
FIGURE 35. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
FIGURE 36. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2030 (USD MILLION)
FIGURE 37. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 38. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 39. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 40. AMERICAS T-CELL IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 41. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 46. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 47. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 48. UNITED STATES T-CELL IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 49. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 51. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 52. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 53. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 61. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 62. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 67. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 68. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 69. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 81. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 82. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 83. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 84. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 85. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 86. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 87. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 88. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 89. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 90. GLOBAL T-CELL IMMUNOTHERAPY MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 91. GLOBAL T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 92. GLOBAL T-CELL IMMUNOTHERAPY MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022List of Tables
TABLE 1. GLOBAL T-CELL IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 66. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 67. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 68. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 69. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 74. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 93. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 95. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 96. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 98. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 100. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 101. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 108. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 109. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 110. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 111. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 138. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 139. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 140. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 141. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 154. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 155. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 156. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 157. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 159. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 160. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 161. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 162. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 164. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 165. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 166. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 167. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 169. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 170. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 171. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 172. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 174. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 175. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 176. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 177. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 184. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 185. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 186. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 187. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 189. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 190. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 191. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 194. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 195. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 196. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 197. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 199. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 200. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 201. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 202. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 204. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 205. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 206. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 207. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 209. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 210. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 211. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 212. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 226. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 227. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 229. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 230. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 231. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 232. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 237. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 239. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 240. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 241. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 242. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 244. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 245. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 246. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 247. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 254. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 256. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 258. GLOBAL T-CELL IMMUNOTHERAPY MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 259. GLOBAL T-CELL IMMUNOTHERAPY MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 260. GLOBAL T-CELL IMMUNOTHERAPY MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 261. GLOBAL T-CELL IMMUNOTHERAPY MARKET RANKING, BY KEY PLAYER, 2022
TABLE 262. GLOBAL T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2022
TABLE 263. GLOBAL T-CELL IMMUNOTHERAPY MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 264. GLOBAL T-CELL IMMUNOTHERAPY MARKET MERGER & ACQUISITION
TABLE 265. GLOBAL T-CELL IMMUNOTHERAPY MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 266. GLOBAL T-CELL IMMUNOTHERAPY MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 267. GLOBAL T-CELL IMMUNOTHERAPY MARKET INVESTMENT & FUNDING
TABLE 268. GLOBAL T-CELL IMMUNOTHERAPY MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 269. GLOBAL T-CELL IMMUNOTHERAPY MARKET: LICENSE & PRICING